iScience (Jan 2022)
Standardized two-step testing of antibody activity in COVID-19 convalescent plasma
- Pavlo Gilchuk,
- Isaac Thomsen,
- Sandra Yoder,
- Eric Brady,
- James D. Chappell,
- Laura J. Stevens,
- Mark R. Denison,
- Rachel E. Sutton,
- Rita E. Chen,
- Laura A. VanBlargan,
- Naveenchandra Suryadevara,
- Seth J. Zost,
- Jonathan Schmitz,
- Jill M. Pulley,
- Michael S. Diamond,
- Jillian P. Rhoads,
- Gordon R. Bernard,
- Wesley H. Self,
- Todd W. Rice,
- Allison P. Wheeler,
- James E. Crowe, Jr.,
- Robert H. Carnahan
Affiliations
- Pavlo Gilchuk
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, 11475 Medical Research Building IV, 2213 Garland Avenue, Nashville, TN 37232-0417, USA
- Isaac Thomsen
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, TN, USA
- Sandra Yoder
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, TN, USA
- Eric Brady
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, TN, USA
- James D. Chappell
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Laura J. Stevens
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Mark R. Denison
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Rachel E. Sutton
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, 11475 Medical Research Building IV, 2213 Garland Avenue, Nashville, TN 37232-0417, USA
- Rita E. Chen
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA
- Laura A. VanBlargan
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
- Naveenchandra Suryadevara
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, 11475 Medical Research Building IV, 2213 Garland Avenue, Nashville, TN 37232-0417, USA
- Seth J. Zost
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, 11475 Medical Research Building IV, 2213 Garland Avenue, Nashville, TN 37232-0417, USA
- Jonathan Schmitz
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Urology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Jill M. Pulley
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA
- Michael S. Diamond
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO, USA
- Jillian P. Rhoads
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA
- Gordon R. Bernard
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Wesley H. Self
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Todd W. Rice
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Allison P. Wheeler
- Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- James E. Crowe, Jr.
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, 11475 Medical Research Building IV, 2213 Garland Avenue, Nashville, TN 37232-0417, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Robert H. Carnahan
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center, 11475 Medical Research Building IV, 2213 Garland Avenue, Nashville, TN 37232-0417, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Corresponding author
- Journal volume & issue
-
Vol. 25,
no. 1
p. 103602
Abstract
Summary: The COVID-19 pandemic revealed an urgent need for rapid profiling of neutralizing antibody responses and development of antibody therapeutics. The current Food and Drug Administration-approved serological tests do not measure antibody-mediated viral neutralization, and there is a need for standardized quantitative neutralization assays. We report a high-throughput two-step profiling approach for identifying neutralizing convalescent plasma. Screening and downselection for serum antibody binding to the receptor-binding domain are followed by quantitative neutralization testing using a chimeric vesicular stomatitis virus expressing spike protein of SARS-CoV-2 in a real-time cell analysis assay. This approach enables a predictive screening process for identifying plasma units that neutralize SARS-CoV-2. To calibrate antibody neutralizing activity in serum from convalescent plasma donors, we introduce a neutralizing antibody standard reagent composed of two human antibodies that neutralize SARS-CoV strains, including SARS-CoV-2 variants of concern. Our results provide a framework for establishing a standardized assessment of antibody-based interventions against COVID-19.
